The Company was incorporated by the Founder for the purposes of being listed on the Main Board as a SPAC to pursue acquisitions of, and investments in, commercial enterprises operating in the Biotech, Biohacking or Pharmaceutical sector that will enable it to develop and expand methodologies by utilising Artificial Intelligence (AI) and expertise of medical specialists to deliver holistic and individualised solutions to customers to better their health, performance and increase their longevity.
The Company intends to obtain a Listing as a SPAC on the Main Board following subscriptions for the Offer Shares pursuant to the IPO.
A SPAC is a public Company, the Shares of which are listed on the JSE. The purpose of a SPAC is to raise capital which must be used to acquire assets that will, on their own, enable the Company to qualify for a Listing, other than as a SPAC, pursuant to the Listing criteria of the JSE. Until such assets are acquired, the only asset of a SPAC is the cash which it holds pursuant to a capital raise through the issue of Shares.
History:
2022:The Company was established by the Founder and incorporated in South Africa on 23 February 2022 as a public Company.
2024: The Company listed on JSE on 25 June 2024.
Headquarters
7 Sterling Street, The Point Office Park, Unit C1,Samrand
Pretoria; Gauteng;
Postal Code: 0157
Contact Details: Purchase the Cilo Cybin Holdings Limited report to view the information.
Website: http://www.cilocybin.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service